Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | STAT3 | P40763 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | CTSD | P07339 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668052 | 0.89 | LMNA (0.49) | LMNASTAT3RAB9ANPC1CTSD | |
| SCHEMBL7038663 | 0.88 | HCRTR1 (0.47) | LMNAGAAMEN1KMT2AKCNK3 | |
| SCHEMBL3766136 | 0.83 | STAT3 (0.52) | LMNASTAT3RAB9ANPC1CTSD | |
| SCHEMBL668599 | 0.81 | LMNA (0.40) | LMNASTAT3RAB9ANPC1CTSD | |
| SCHEMBL29778078 | 0.81 | ABCB1 (0.52) | STAT3RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL7039865 | 0.81 | ABCB1 (0.52) | STAT3RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL3767637 | 0.81 | CTSD (0.68) | LMNASTAT3RAB9ANPC1CTSD | |
| SCHEMBL22069493 | 0.79 | TAS1R3 (0.47) | LMNASTAT3RAB9ANPC1CTSD | |
| SCHEMBL20379692 | 0.79 | HDAC3 (0.46) | LMNASTAT3RAB9ANPC1CTSD | |
| SCHEMBL14764985 | 0.79 | TAS1R3 (0.47) | LMNASTAT3RAB9ANPC1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778157-A | Crystalline diacylhydrazine and uses thereof | 英特瑞克斯顿股份有限公司 | 2021-05-11 | — | — | CN | claimed |
| CN-118159653-A | Chimeric receptor therapies | 普雷西根公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-110139933-B | Ataxin expression constructs | 英特瑞克斯顿股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-117203342-A | Human papillomavirus vaccine and use thereof for HPV related diseases | 普雷西根公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-113226337-A | In vivo controlled combination therapy for the treatment of cancer | 普莱西根股份有限公司 | 2021-08-06 | — | — | CN | disclosed |
| CN-112778157-A | Crystalline diacylhydrazine and uses thereof | 英特瑞克斯顿股份有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-112778157-A | Crystalline diacylhydrazine and uses thereof | 英特瑞克斯顿股份有限公司 | 2021-05-11 | — | — | CN | disclosed |
| CN-112714769-A | ROR-1 specific chimeric antigen receptor and uses thereof | 普瑞赛格恩公司 | 2021-04-27 | — | — | CN | disclosed |
| CN-112672753-A | Fusion constructs and methods of use thereof | 普瑞赛格恩公司 | 2021-04-16 | — | — | CN | disclosed |
| CN-112533957-A | MUC 16-specific chimeric antigen receptor and uses thereof | 普瑞赛格恩公司 | 2021-03-19 | — | — | CN | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| EP-1601642-A4 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE INC (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1601642-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene, Inc. (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004078924-A2 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| EP-0982292-B1 | Process for the preparation of monoacylhydrazines using carboxylic acids | DOW AGROSCIENCES LLC (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6096890-A | Process for substituted hydrazides using carboxylic acids | ROHM AND HAAS COMPANY (US) | 2000-08-01 | — | — | US | disclosed |
| EP-0982292-A2 | Process for the preparation of monoacylhydrazines using carboxylic acids | ROHM AND HAAS COMPANY (US) | 2000-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | NR2E3, NR5A1, NR5A2 | LMNA 3692/4885STAT3 393/4885RAB9A 4777/4885 |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, NR5A1, NR5A2 | LMNA 3692/4885STAT3 393/4885RAB9A 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.